Form 4: QuidelOrtho Director Ann D. Rhoads Receives Significant Restricted Stock Unit Grants

Ann D. Rhoads, a Director at QuidelOrtho Corp, was granted a total of 8,780 Restricted Stock Units (RSUs) on May 29, 2025, as part of her compensation and deferred fee arrangements.

Summary

• Ann D. Rhoads, a Director of QuidelOrtho Corp (QDEL), was granted a total of 8,780 Restricted Stock Units (RSUs) on May 29, 2025.
• This includes an equity grant of 6,829 RSUs, which will vest on May 29, 2026.
• An additional 1,626 RSUs were received in lieu of cash payments for retainer and Board service-related fees under a deferred compensation program for non-employee directors. These 1,626 RSUs have a staggered vesting schedule: 406 shares vested on May 29, 2025, 406 shares will vest on August 29, 2025, and 814 shares (407 + 407) will vest on November 29, 2025.
• A further 325 RSUs were granted as a "Premium" and will vest on May 29, 2026.
• Each RSU represents the right to receive one share of QuidelOrtho Corporation common stock.
• Following these transactions, Ann D. Rhoads beneficially owns 8,780 Restricted Stock Units directly.

Sentiment

Score: 6

Explanation: The document reports a routine grant of Restricted Stock Units to a director as part of their compensation. This is a standard practice that aligns director interests with shareholders and is generally viewed as neutral to slightly positive, as it reflects ongoing corporate governance and compensation practices without indicating any immediate operational or financial distress or exceptional positive news.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Ann D. Rhoads aligns her interests with those of shareholders, as the value of her compensation is tied to the company's stock performance.
• The use of RSUs in lieu of cash payments for certain fees under a deferred compensation program can help conserve cash for the company.

Negatives

• The issuance of new Restricted Stock Units, upon vesting and conversion to common stock, will result in a minor dilution of existing shareholders' equity.

Future Outlook

NA

Industry Context

The practice of granting Restricted Stock Units (RSUs) to non-employee directors is a common compensation strategy across various industries, including the healthcare diagnostics sector where QuidelOrtho operates. This method is widely used to align director incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The granting of Restricted Stock Units (RSUs) as part of director compensation is a standard practice in publicly traded companies, including those in the diagnostics and medical device industry.
• While specific grant sizes vary based on company size, performance, and board compensation policies, the mechanism of using equity to align director interests is consistent with global benchmarks.
• For example, companies like Abbott Laboratories (ABT) and Danaher Corporation (DHR), also active in diagnostics, frequently utilize equity-based compensation for their non-executive directors to foster long-term commitment and performance alignment.
• The deferred compensation program allowing RSUs in lieu of cash is also a common feature in sophisticated compensation plans for non-employee directors.

Related Party Transactions

• The grant of Restricted Stock Units to Ann D. Rhoads, a Director, constitutes a transaction with a related party (an insider). This is a standard compensation arrangement for non-employee directors.

Stakeholder Impact

• Shareholders: Minor potential dilution upon vesting of RSUs, but also improved alignment of director interests with shareholder value.
• Director (Ann D. Rhoads): Receives equity compensation, aligning her financial interests with the company's long-term performance.

Next Steps

• Vesting of 406 shares of converted Restricted Stock Units on August 29, 2025.
• Vesting of 814 shares of converted Restricted Stock Units on November 29, 2025.
• Vesting of 6,829 Restricted Stock Units (Equity Grant) and 325 Restricted Stock Units (Premium) on May 29, 2026.

Key Dates

Keywords

QuidelOrtho Corp, QDEL, SEC Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, Deferred Compensation, Stock Vesting